Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of E10030 plus Lucentis versus Lucentis alone in neovascular age-related macular degeneration
2010-018741-65Phase 2Completed
- Sponsor
- IVERIC bio
- Start
- Mar 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in exudative macular degeneration, subfoveal choroidal neovascularization (CNV) and age-related macular degeneration (AMD) comparing E10030 + Lucentis with Lucentis monotherapy (2 arms). Primary endpoint: Mean change in visual acuity from baseline at Week 24. Started Mar 2010; status: completed.
02
Drugs
pegpleranibranibizumab
03
Conditions
exudative macular degenerationsubfoveal choroidal neovascularization (CNV)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2010-018741-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018741-65.